MX2007005125A - Compuestos y composiciones como moduladores de la senda de hedgehog. - Google Patents

Compuestos y composiciones como moduladores de la senda de hedgehog.

Info

Publication number
MX2007005125A
MX2007005125A MX2007005125A MX2007005125A MX2007005125A MX 2007005125 A MX2007005125 A MX 2007005125A MX 2007005125 A MX2007005125 A MX 2007005125A MX 2007005125 A MX2007005125 A MX 2007005125A MX 2007005125 A MX2007005125 A MX 2007005125A
Authority
MX
Mexico
Prior art keywords
function
compositions
compounds
hedgehog pathway
gain
Prior art date
Application number
MX2007005125A
Other languages
English (en)
Inventor
Xu Wu
Peter G Schultz
Sheng Ding
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2007005125A publication Critical patent/MX2007005125A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion proporciona un metodo para modular la actividad de la senda de senalizacion de Hedgehog. En particular, la invencion proporciona un metodo para inhibir los estados de crecimiento aberrantes resultantes de los fenotipos tales como perdida de funcion de Ptc, ganancia de funcion de Hedgehog, ganancia de funcion de Smoothened, o ganancia de funcion de Gli, el cual comprende poner en contacto una celula con una cantidad suficiente de un compuesto de la Formula I.
MX2007005125A 2004-10-28 2005-10-28 Compuestos y composiciones como moduladores de la senda de hedgehog. MX2007005125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62344404P 2004-10-28 2004-10-28
PCT/US2005/039442 WO2006050351A2 (en) 2004-10-28 2005-10-28 Compounds and compositions as hedgehog pathway modulators

Publications (1)

Publication Number Publication Date
MX2007005125A true MX2007005125A (es) 2007-07-04

Family

ID=36319759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005125A MX2007005125A (es) 2004-10-28 2005-10-28 Compuestos y composiciones como moduladores de la senda de hedgehog.

Country Status (11)

Country Link
US (1) US20090209573A1 (es)
EP (1) EP1804803A4 (es)
JP (1) JP2008518954A (es)
KR (1) KR20070083836A (es)
CN (1) CN101083996A (es)
AU (1) AU2005302279A1 (es)
BR (1) BRPI0517253A (es)
CA (1) CA2583812A1 (es)
MX (1) MX2007005125A (es)
RU (1) RU2007119637A (es)
WO (1) WO2006050351A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1709019E (pt) 2004-01-12 2007-08-27 Serono Lab Derivados de tiazol e sua utilização
ITVA20060041A1 (it) * 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
TW200901987A (en) 2007-04-18 2009-01-16 Merck & Co Inc Triazole derivatives which are Smo antagonists
WO2009051909A1 (en) * 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009299927B2 (en) 2008-10-01 2013-05-30 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
WO2011085128A1 (en) 2010-01-07 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
EP4438734A2 (en) 2010-06-14 2024-10-02 The Scripps Research Institute Reprogramming of cells to a new fate
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
EP2723744B1 (en) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
CA2875057C (en) 2012-07-09 2021-07-13 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyrazine compounds and their use as inhibitors of the phosphodiesterase 10 enzyme
MX2020009849A (es) 2012-11-01 2021-09-13 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US20140377258A1 (en) 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
CN110494431B (zh) * 2017-09-30 2022-11-04 苏州浦合医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PL340589A1 (en) * 1997-11-11 2001-02-12 Pfizer Prod Inc Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
AU2001237401B2 (en) * 2000-03-01 2006-11-09 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
AU2001242629B2 (en) * 2000-03-29 2005-08-11 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
AU2001252609A1 (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
AU2001295992A1 (en) * 2000-10-24 2002-05-06 Sankyo Company Limited Imidazopyridine derivatives
CA2460909A1 (en) * 2001-09-28 2003-04-10 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds
WO2003088970A2 (en) * 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
KR100530988B1 (ko) * 2003-03-14 2005-11-28 한국과학기술원 봉입체 결합 단백질을 코딩하는 유전자를 결핍시키거나 증폭시켜 목적 단백질을 제조하는 방법
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
PT1709019E (pt) * 2004-01-12 2007-08-27 Serono Lab Derivados de tiazol e sua utilização
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds

Also Published As

Publication number Publication date
WO2006050351A2 (en) 2006-05-11
WO2006050351A3 (en) 2007-02-22
EP1804803A2 (en) 2007-07-11
RU2007119637A (ru) 2008-12-10
KR20070083836A (ko) 2007-08-24
BRPI0517253A (pt) 2008-10-07
JP2008518954A (ja) 2008-06-05
CN101083996A (zh) 2007-12-05
CA2583812A1 (en) 2006-05-11
EP1804803A4 (en) 2008-07-30
AU2005302279A1 (en) 2006-05-11
US20090209573A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
MX2007005125A (es) Compuestos y composiciones como moduladores de la senda de hedgehog.
TNSN08437A1 (en) Compounds and compositions as hedgehog pathway modulators
WO2008014291A3 (en) Compounds and compositions as hedgehog signaling pathway modulators
WO2010027746A3 (en) Hedgehog pathway modulators
MX2009013273A (es) Derivados de bifenil-carboxamida como moduladores de la senda de hedgehog.
WO2007120827A3 (en) Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
WO2003088970A3 (en) Modulators of hedgehog signaling pathways, compositions and uses related thereto
EP1482928A4 (en) MEDIATOR OF IGEL SIGNALING PATCHES, COMPOSITIONS AND RELEVANT USES
WO2005033288A3 (en) Hedgehog pathway antagonists
WO2006079021A3 (en) Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
WO2008002671A3 (en) Metalloprotease inhibitors
MX2007000392A (es) Derivados de 2-pirrolidona sustituida como fungicidas e insecticidas.
WO2009066967A3 (en) Microrna antisense pnas, compositions comprising the same, and methods for using and evaluating the same
EP1864670A4 (en) INHIBITOR OF SUCRASE ACTIVITY, INHIBITOR OF GLUCOAMYLASE ACTIVITY AND FOOD AND FOOD CONTAINING THESE
WO2005033048A3 (en) Wnt pathway antagonists
MX266924B (es) Composiciones de recubrimiento por electrodeposicion catodica que contienen un agente anti-crater.
HK1101667A1 (en) 5-iodotetrazoles
WO2009068193A3 (de) Herbizid-azol-kombination
WO2007064997A3 (en) Compounds and methods for inhibiting apoptosis
FI20055120A0 (fi) Menetelmä mikro-organismien kasvun estämiseksi
TH98278A (th) สารประกอบและองค์ประกอบเป็นตัวควบคุมวิถีเฮดจ์ฮอก
WO2008035230A3 (en) Liquid compositions comprising substantially purified igf at or below ph 5.0
GB0305731D0 (en) Self contained horticultural growth system
UA46479U (en) 5-AMINE-7-(4-SUBSTITUTED PHENYL)-4,7-DIHYDRO[1,2,4]TRIASOLOL-[1,5-а]PYRIMIDINE-6-CARBONITRILES POSSESSING ANTICONVULSANT ACTIVITY
UA6153U (en) A method for oil and oil products purification from sulphur compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal